Pharmacy Times

GPhA OUTLINES AGENDA FOR NEW FDA COMMISSIONER

Author:

Officials at the Generic Pharmaceutical Association (GPhA) are wasting no time in letting incoming FDA Commissioner Andrew von Eschenbach, MD, know what they will be expecting from him. In a statement welcoming Dr. von Eschenbach to the FDA, GPhA President and Chief Executive Officer Kathleen Jaeger said that the appointment of "a permanent commissioner is an absolute necessity at a federal agency that has such a direct impact on the health and well-being of America's citizens."

Jaeger urged the new FDA chief to move quickly "to appropriately address important issues, such as an abbreviated approval pathway for generic biopharmaceuticals, authorized generics, the timely approval of generic medicines, and increased funding for the Office of Generic Drugs."